Fig. 2
a. Kaplan Meier curves of FDG PET parameters and Progression free survival after ipilimumab. b. Kaplan Meier curves of FDG-PET parameters and Progression free survival after anti-PD1. c. Kaplan Meier curves of FDG-PET parameters and overall survival from the start of first line immunotherapy. d. Kaplan Meier curves of Spleen to Liver Ratio (SLR) and overall survival after ipilimumab and anti-PD1 respectively. (A) and (B). Kaplan Meier survival curves for progression free survival after ipilimumab or anti-PD1 and its correlation for SUVmax, Metabolic Tumour Volume (MTV) and spleen to liver ratio (SLR) respectively. High SLR was significantly correlated with PFS after ipilimumab (median PFS 1.0 vs 3.0 months, HR 3.14, p = 0.008), but was not associated with PFS after anti-PD1 (median 3.0 vs 3.0 months, HR 0.56, p = 0.324). Figure 2(c) High SLR was associated with poor OS after first line immunotherapy (ipilimumab or anti-PD1), median 1 vs 14 months; HR 3.92, p = 0.003. Neither SUVmax nor MTV was significantly associated with PFS or OS after either treatment. Figure 2(D) High SLR was associated with poor OS after ipilimumab (median 1 v 21 months, HR 5.83, p = 0.0001. High SLR was not associated with OS after anti-PD1 treatment (median 8.8 v 9.7 months; HR 0.92, p = 0.89)